Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Sekur Private Data Signs Distribution Agreement In Africa (click to learn more) Pinnacle Discovers Silver-Lead-Zinc Mineralization Following up on LiDAR Survey at El Potrero (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Context Therapeutics Inc CNTX

Healthcare Biotechnology
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the... see more

Current News (NDAQ:CNTX)

Context Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire February 9, 2026

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 16, 2026

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

GlobeNewswire November 7, 2025

Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results

GlobeNewswire November 5, 2025

Context Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire October 28, 2025

Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

GlobeNewswire October 6, 2025

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 3, 2025

Context Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire August 27, 2025

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

GlobeNewswire August 6, 2025
View More News ››

Opinion & Analysis (NDAQ:CNTX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CNTX)

Using technical analysis for this stock.

This stock is a big bargain at these low prices per share,so that it is a big BUY for you guys out there.Well,it is signalling strength...
coolfooldumbguy - January 5, 2026

CNTX: Promising Bispecific Antibody Candidate Poised for Cli

http://beyondspx.com/2024/07/31/cntx-promising-bispecific-antibody-candidate-poised-for-clinical-advancement/
MikeTester - August 2, 2024

RE:CNTX...... mini pop to $1.15

SILO....... pop....now $3.65 Shoulda coulda
Iseneschal - February 2, 2023

CNTX...... mini pop to $1.15

I like to leave some for the next guy ; )  Cheers............oh....take a look at SILO on NASDAQ...share buyback! $2.75 u.s
Iseneschal - January 31, 2023

CNTX ....still climbing the RBL

$1.10 Me ...no position ; )
Iseneschal - January 31, 2023

CNTX.... vols are increasing and so is the

Share price  On watch
Iseneschal - January 31, 2023
View more Bullboard ››

TomaGold Corp.

TomaGold Corp.

TomaGold Corporation, together with its subsidiaries, engages in the acquisition, exploration, assessment, and development of ...
View More »

Podcasts